HawkPartners has extensive experience working across the healthcare industry, including work with both large and small pharmaceutical companies, medical device manufacturers, insurers, health systems and cross-vertical healthcare providers. Our work in healthcare spans the full array of marketing strategy and market research engagements, including developing and testing marketing communications, assessing market opportunities and potential demand, and defining market segments to drive effective targeting. We have deep expertise in gathering insights from the full range of key stakeholders in healthcare and synthesizing those perspectives to provide thoughtful guidance for our clients. We welcome the conversation.
Statistics and investments point to pharma companies’ integration of transformative technologies into ways of thinking and doing business. The infographic below, developed by Abbey Ahearn and Lucy Hale, demonstrates the rising emphasis of digital health in pharma.
Healthcare brands should take a patient-centered approach when preparing for launch. Learn why organizations need to build a deeper, more holistic understanding of the ecosystem of influences affecting patient outcomes.
HawkPartners offers five examples to optimize public health communications materials
The emergency-use authorizations of COVID-19 vaccines are priming consumers for vaccine brand differentiation and presenting a novel marketing situation that tasks marketers with challenging master brand decisions.
During a recent Advertising Research Foundation Pharma Council event, Robert Duboff moderated a discussion of how behavioral economics can provide greater insight into the COVID-19 patient journey.
The current pandemic is tearing down the regulatory and reimbursement barriers that have prevented telehealth from realizing its full potential to date. Our team examines the value propositions of several telehealth providers as the industry enters the next stage of growth.
HawkPartners developed a five-step framework to help pharma companies anticipate the “new normal” as a means of optimizing HCP engagement in a post-COVID-19 world.
With the growing trend of real-world data and real-world evidence in healthcare, what can we expect moving forward? Sharon Mowen explores these applications across the product life cycle and what it means for the future of healthcare decisions.
Statistics and investments point to pharma companies’ integration of transformative technologies into ways of thinking and doing business. The infographic below, developed by Abbey Ahearn and Lucy Hale, demonstrates the rising emphasis of digital health in pharma.
Amidst explosive investment in digital health, the industry is working to keep the human side of care front and center.